Food manufacturers are confronting a significant challenge that has the potential to transform the entire sector.

The catalyst is GLP-1 medications, better known as weight-loss drugs.

The surge in popularity of these treatments is forcing food companies to wrestle with entirely new consumer expectations.

In this episode of the Food Matters Live podcast, made in partnership with IFF, we ask: how do you develop products for people whose fundamental relationship with eating has been altered?

This extends beyond just current users of the medication, it encompasses those contemplating treatment, people who have discontinued it, and even people for whom the wider discussion has shifted their perspective on taste, texture and nutrition.

GLP-1 treatments present manufacturers with both substantial product development challenges and remarkable possibilities.

IFF (NYSE: IFF) makes joy through science, creativity and heart. As the global leader in flavours, fragrances, food ingredients, health and biosciences, they deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.